Abacus Global (ABX) Q3 2026 Earnings Call Transcript

Abacus Global Management reported Q3 2026 revenue of $76.9 million, up 22% year over year, and adjusted net income of $29.4 million, above its $26 million–$28 million guidance range. The company raised full-year adjusted net income guidance to $104.5 million–$106.5 million and adjusted EPS guidance to $1.05–$1.07, with top-end EPS growth of 24% over 2025. A $400 million securitization was twice oversubscribed; Q3 longevity-fund inflows were $452.4 million, while Abacus also announced a 10% increase in its annual dividend to $0.22 per share.

Analysis

The key underwriting question is whether ABX is converting a balance-sheet-intensive, transaction-driven business into a repeatable fee-and-servicing model—or simply accelerating asset sales and recognizing gains sooner. The 3x turnover is flattered by quarter-end securitization timing, while realized gains remain sensitive to funding costs, policy mix and buyer appetite; management’s 1.5–2x turnover and 20% gain assumptions are more prudent anchors than this quarter’s levels. Cash conversion is encouraging, but some cash came from gains booked in prior periods, so it does not yet establish steady-state earnings quality.

The securitization channel could lower marginal funding costs and let ABX recycle equity faster. If repeat issuance holds, it may also improve the company’s bargaining position against smaller life-settlement originators competing for policies. The counter-risk is that a single oversubscribed transaction is not proof of durable capacity: insurer demand, note pricing, collateral eligibility and residual economics matter. The $400 million structure includes a residual; it should not be treated as $400 million of cash proceeds or recurring revenue.

Near term, raised guidance and capital returns support sentiment, but adjusted earnings are gross of estimated tax effects and Life Solutions growth is gain-heavy. Over 1–3 months, verify the Q4 fee/AUM recovery management forecast and inspect filings for securitization proceeds, costs and retained-risk details. Over 6–18 months, the central catalyst is repeat issuance plus fund distribution; LifeARC inquiries and partner interest are not yet demonstrated recurring revenue. Contrarian view: strong originations and inflows may be drawing attention away from the gap between 11% current fee-related revenue and the 70% 2030 goal.

Key Decisions for Investors

• Do not chase the earnings beat on headline growth alone. Treat ABX as a conditional, staged long: consider an initial position only on a meaningful post-event pullback, and add only after filings substantiate positive securitization contribution and recurring fee growth. No price target is supportable from the supplied data.
• Use the Q4 report and planned Q1 2027 securitization as gates. Track fee-related revenue/AUM, repeat-issue pricing and size, realized gains, turnover, and operating cash flow excluding prior-period gain realization. A sustained move toward the stated 1.5–2x turnover range with gains near or below management’s 20% planning assumption would weaken the growth case.
• Before sizing, verify the cash-flow bridge, securitization note costs and residual funding/retained risk, debt maturities and refinancing terms, and interval-fund platform flows/redemption terms. These determine whether faster asset recycling actually improves per-share earnings and liquidity rather than shifting risk off the visible balance sheet.